# AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients

> **NCT06489197** · PHASE2 · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 30 (estimated)

## Conditions studied

- ESCC
- Advanced Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Ivonescimab combined with albumin paclitaxel and cisplatin

## Key facts

- **NCT ID:** NCT06489197
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-16
- **Primary completion:** 2026-10-30
- **Final completion:** 2027-08-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06489197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06489197, "AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06489197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*